KRAS and pancreatic neoplasm: Consistent with previous reports regarding native albumin, transient KRASG12D overexpression in KRAS wt BxPC-3 cells and inducible KRASG12D expression in tumor cells derived from a genetically engineered mouse model of pancreatic cancer, both enhanced nab-PTX uptake by ≥8-fold.